John Hansbury and Sherry Jacobson elected Co-Presidents, Raynor Dahlquist and Bronwen Smith join Board of Directors New York, NY October 19, 2011— Ovarian Cancer Research Fund (OCRF) is pleased to announce the election of Co-Presidents to its Board of Directors, John W. Hansbury, Esq., and Sherry Jacobson. Hansbury and Jacobson have both served on the … Continued
In 1999, a small group of ovarian cancer survivors decided to get together to provide support for each other. The next year, they held the first walk/run in Minnesota for ovarian cancer. The organizers were surprised when hundreds of people joined the walk and raised $91,000. It brought home the message that there was a … Continued
(New York, NY – October 4, 2011) – A unique support program that pairs women with gynecologic cancer with volunteers who have survived the disease is coming to NewYork-Presbyterian Hospital. The national Woman to Woman program, funded by Ovarian Cancer Research Fund (OCRF), was first established at The Mount Sinai Medical Center, and OCRF plans … Continued
The Cancer Support Community (CSC) is one of the Ovarian Cancer National Alliance’s national Partner Members, a relationship that strengthens both groups. Vice President of Education and Outreach Ivy Ahmed notes: “We’re not a tumor specific organization—we serve people with all cancer types. Being a Partner Member of the Alliance helps us provide resources specific … Continued
08/17/2011Researchers in the United Kingdom have discovered a new genetic mutation that increases the risk for ovarian cancer. This major finding was published online in the journal Nature Genetics on August 7th. Much like the BRCA1 and BRCA2 mutations, which were discovered in the 1990s and which also increase a woman’s risk for ovarian cancer, … Continued
08/09/2011 Earlier this year, OCRF welcomed two new members to its Scientific Advisory Committee: Ronny I. Drapkin, MD, PhD and Sandra Orsulic, PhD. Both Drs. Drapkin and Orsulic are experts in ovarian cancer research, and bring valuable additional experience to our now thirteen-member Scientific Advisory Committee. In addition, both are past recipients of OCRF grants. … Continued
Drop by the Petaluma Arts Center on September 2, and you will find a building bedecked in teal. The Women’s Cancer Awareness Group is using “yarn-bombing”—decorating a public structure or space with yarn—to raise awareness of ovarian cancer. Groups of knitters have gathered once a week to create teal items for the project; those who … Continued
The Ovarian Cancer National Alliance’s 14th Annual Conference, “Turning Promise into Action,” just wrapped up. What a conference it was! Hundreds of researchers, clinicians, survivors and caregivers attended the largest ovarian cancer-specific conference in the country. They learned about the latest in research, diagnosis, treatment and quality of life for women with ovarian cancer. This … Continued
When Jean Shipos survived a recurrence of ovarian cancer in 2003, she and her daughter vowed to raise awareness of the disease. They got involved with a local run/walk, organizing a team and fundraising each year. In 2006, Jean’s daughter suggested starting an event of their own. “We can’t keep hitting up the same friends … Continued
In a paper published on June 30, 2011 in the journal Nature, researchers working as part of The Cancer Genome Atlas (TCGA) Research Network report that they have created a genetic “map” of ovarian cancer. This important work, which is the largest study of any tumor type to date, will help researchers better understand the … Continued
Kelly Smith founded the Ovarian Cancer Alliance of North Florida while she was on spring break from college one year. Based in Tallahassee, this Partner Member focuses on younger women, including the many college students who attend schools in northern Florida. Kelly herself was diagnosed with ovarian cancer at age 17—about the age of the … Continued
Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed.
Get email updates about research news, action alerts, and ways to join the fight.
